The combination of weekly trastuzumab plus vinorelbine may be preferable regimen in HER-2 positive breast cancer patients with brain metastasis

Journal of Oncology Pharmacy Practice

Volumn 21, Issue 4, 2015, Pages 310-312

  Mutlu, Hasan ^a   Büyükçelik, Abdullah ^b  

^a AKDENIZ UNIVERSITY   (Turkey)

^b ACIBADEM UNIVERSITY   (Turkey)

Author keywords

brain metastasis; Breast cancer; herceptin; trastuzumab; vinorelbine

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; ETOPOSIDE; FLUOROURACIL; NAVELBINE; PACLITAXEL; PROGESTERONE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; VINBLASTINE;

ABDOMINAL RADIOGRAPHY; ADULT; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; BRAIN METASTASIS; BREAST CANCER; CANCER GRADING; CANCER HORMONE THERAPY; CANCER SURVIVAL; CASE REPORT; FEMALE; GAMMA KNIFE; HEADACHE; HUMAN; LIVER METASTASIS; MASTECTOMY; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PREMENOPAUSE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; BREAST NEOPLASMS; DRUG ADMINISTRATION; GENETICS; SECONDARY;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; RECEPTOR, ERBB-2; TRASTUZUMAB; VINBLASTINE;

EID: 84936994807     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155214531514     Document Type: Article

References (12)

1. Stewart DJ,. A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors. J Neurooncol 1994; 20: 121-139.
2. Eichler AF, Loeffler JS,. Multidisciplinary management of brain metastases. Oncologist 2007; 12: 884-898.
3. Wen PY, Loeffler JS,. Management of brain metastases. Oncology (Williston Park) 1999; 13: 941-954.
4. Cameron D, Casey M, Press M,. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008; 112: 533-543.
5. Lin NU, Winer EP,. Brain metastases: the HER2 paradigm. Clin Cancer Res 2007; 13: 1648-1655.
6. Gaspar L, Scott C, Rotman M,. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997; 37: 745-751.
7. Bachelot T, Romieu G, Campone M,. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol 2013; 14: 64-71.
8. Larsen PB, Kümler I, Nielsen DL,. A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer. Cancer Treat Rev 2013; 39: 720-727.
9. Kaplan MA, Isikdogan A, Koca D, et al. Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Society of Medical Oncology. Breast Cancer 2013 Jan 19. [Epub ahead of print].
10. Mehta AI, Brufsky AM, Sampson JH,. Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier. Cancer Treat Rev 2013; 39: 261-269.
11. Andersson M, Lidbrink E, Bjerre K,. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J Clin Oncol 2011; 29: 264-271.
12. Ruth O'Regan, Mustafa Ozguroglu, Fabrice Andre, et al. Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3). J Clin Oncol 2013;31 (suppl; abstr 505).